On August 29th, 2023, the U.S. HHS recommended to the DEA that cannabis be reclassified from a Schedule I drug to a Schedule III drug. Rescheduling...
The FDA abdicates from pursuing rulemaking to allow the use of CBD in dietary supplements or conventional foods, as it cannot find adequate evidence to determine...